Melanoma Drug

Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the melanoma drug market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[194 Pages Report] The Melanoma Drug Market size was estimated at USD 5.40 billion in 2023 and expected to reach USD 5.81 billion in 2024, at a CAGR 8.32% to reach USD 9.45 billion by 2030.

Melanoma Drug Market
To learn more about this report, request a free PDF copy

Melanoma drugs are a class of pharmaceutical agents specifically designed to treat melanoma, a type of skin cancer. These drugs can be categorized into various types, including immunotherapies, targeted therapies, chemotherapy, and oncolytic virus therapy. Increasing prevalence of melanoma globally, driving innovations in therapeutics. In addition, growing government investments in the healthcare sector and the expansion of reimbursement policies drive market growth. However, the high costs associated with drug development and treatment impact the market growth. Stringent regulatory policies and lengthy approval processes create hindrances to ongoing research and development activities. Furthermore, emerging need for targeted therapy owing to reduced side effects and higher efficiency poses significant opportunities for market growth.

Melanoma Drug Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma

Acral Lentiginous Melanoma (ALM) is the least common subtype of melanoma, typically occurring on the palms, soles, or under the nails. The need for drugs in this category stems from its late diagnosis and the difficulty in treatment due to the lack of visible warning signs. Lentigo Maligna Melanoma (LMM) is commonly found in elderly patients with a history of chronic sun exposure. The drugs in this segment often focus on the molecular and genetic profiles of tumors since they tend to grow slowly and superficially. Nodular Melanoma (NM) is known for its rapid and aggressive growth, often invading deeper layers of the skin within months. End-users prioritize rapid-acting therapies with the potential to shrink nodules and improve surgical outcomes. Superficial Spreading Melanoma (SSM) is the most common type of melanoma, usually presenting as a spreading mole on the skin. Drug preferences for SSM typically involve medications with preventive and long-term management capabilities alongside treatments that can address metastasis.

Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma

Adjuvant therapy in melanoma refers to treatments given after primary therapies, such as surgery, with the intent to eliminate residual disease and reduce the risk of relapse. Common adjuvant therapies include immunotherapies and targeted therapies. Biochemotherapy combines biological treatment with chemotherapy for melanoma patients. The need for this therapy arises when melanoma has spread and is not responding well to other treatments. It is a more aggressive treatment option and is often considered when the disease is in an advanced stage. Chemotherapy drugs, such as dacarbazine, have historically been used for treating metastatic melanoma but have now largely been replaced by newer therapies. The preference arises primarily when other treatment options are contraindicated or the tumor does not harbor actionable mutations. Immunotherapy drugs, such as checkpoint inhibitors, improve the immune system's ability to detect and destroy cancer cells. Their preference is typically for advanced melanoma, including unresectable and metastatic stages. Oncolytic virus therapy employs genetically modified viruses that selectively infect and destroy cancer cells. Preference for this therapy typically arises for patients with injectable lesions and limited disease spread. Targeted therapy drugs act on specific molecular targets associated with cancer and are preferred for patients with identifiable genetic mutations in their tumors, such as BRAF V600 mutations. These drugs have transformed the treatment landscape for metastatic melanoma.

Distribution Channel: Rising demand of online channel due to convenience and telehealth support

Offline distribution channels for melanoma drugs predominantly include hospital pharmacies, retail pharmacies, and clinics. These traditional channels have been the backbone of pharmaceutical distribution due to their wide reach, patient accessibility, and capability to provide in-person professional medical advice and consultation. The online distribution channel for melanoma drugs is rapidly growing, facilitated by technological advances and changing consumer preferences. Online pharmacies and drug delivery services offer patients the convenience of home delivery, often with the support of digital platforms that allow for prescription management, reminders, and telehealth consultations. Offline channels offer in-person professional guidance and immediate access to medication, which is crucial for patients in urgent need of treatment. Conversely, online channels provide convenience, lower prices, and the ability to reach a wider geographic patient base.

Regional Insights

The Americas have a significant market for melanoma drugs due to a higher incidence of skin cancer. Advanced healthcare infrastructure, high awareness regarding melanoma, and reimbursement policies contribute to robust consumer needs. In the United States, the melanoma drug market is driven by innovation in targeted therapies and immunotherapies, supported by the FDA's expedited approvals for promising treatments. Patient assistance programs and insurance coverage often influence customer purchasing behavior. Europe's melanoma drug market is highly regulated, with an emphasis on efficacious and cost-effective treatments. The European Union (EU) countries exhibit high consumer needs due to increasing melanoma cases and the presence of well-established healthcare systems. The adoption of new treatments is influenced by European Medicines Agency (EMA) regulations and HTA (Health Technology Assessment) bodies that assess the value of new medications. European Union initiatives supporting the ongoing research and development activities in melanoma drugs. Middle Eastern countries exhibit growing investment in healthcare and a rising need for innovative treatments. The Asia Pacific region is experiencing a surge in melanoma cases, with countries including China, Japan, and India contributing significantly to rising consumer needs. In APAC, increased investment in healthcare and innovation has begun to reshape the market. Melanoma drug market in APAC benefits from a combination of government initiatives and a strong pipeline of treatments in clinical trials.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Melanoma Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Melanoma Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years

    Moderna, Inc. and Merck KGaA have announced encouraging three-year follow-up results from their phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating the innovative mRNA-4157 (V940) adjuvant therapy in combination with Merck's KEYTRUDA for resected high-risk melanoma patients. The study revealed a 49% reduction in recurrence or mortality risk compared to KEYTRUDA alone, highlighting the substantial potential of combining Moderna's bespoke mRNA technology with established immunotherapies. [Published On: 2023-12-14]

  • Sun Pharma and Philogen’s Melanoma Drug Shows Promising Outcome in Phase 3 Trial

    Philogen S.p.A., in conjunction with Sun Pharma, has revealed encouraging findings from their phase III PIVOTAL trial (NCT02938299) assessing the efficacy of Nidlegy (Daromun) in treating locally advanced, fully resectable melanoma. This pivotal study, involving 257 patients across 22 European clinical centers, demonstrated the benefits of a neoadjuvant intratumoral Nidlegy regimen followed by surgical removal, compared to surgery as a stand-alone treatment. Furthermore, on May 30, 2023, Philogen and Sun Pharma secured a distribution, license, and supply pact to commercialize Nidlegy in Europe, Australia, and New Zealand, aiming to offer a pioneering neoadjuvant immunotherapy solution to patients with resectable advanced melanoma. [Published On: 2023-10-16]

  • U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

    Bristol Myers Squibb has announced the FDA approval of Opdivo (nivolumab) as adjuvant therapy for adults and children aged 12 and over with stage IIB or IIC melanoma following complete surgical resection. This expanded indication builds upon Opdivo's current approvals, further accentuating the company's dedication to melanoma patient care. The FDA’s decision was supported by results from the Phase 3 CheckMate -76K trial, which demonstrated a remarkable 58% reduction in the risk of recurrence or death (HR 0.42; P<0.0001), indicating substantially improved one-year recurrence-free survival rates for Opdivo compared to placebo. [Published On: 2023-10-13]

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int’l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Acral Lentiginous Melanoma
    • Lentigo Maligna Melanoma
    • Nodular Melanoma
    • Superficial Spreading Melanoma
  • Product
    • Adjuvant Therapy
    • Biochemotherapy
    • Chemotherapy Drugs
      • Dacarbazine (DTIC-Dome)
      • Temozolomide (Temodar)
    • Immunotherapy Drugs
      • Checkpoint Inhibitors
      • CTLA-4 Inhibitors
    • Oncolytic Virus Therapy
    • Targeted Therapy Drugs
      • BRAF Inhibitors
      • MEK Inhibitors
  • Distribution Channel
    • Offline
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Melanoma Drug Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Melanoma Drug Market?
  3. What are the technology trends and regulatory frameworks in the Melanoma Drug Market?
  4. What is the market share of the leading vendors in the Melanoma Drug Market?
  5. Which modes and strategic moves are suitable for entering the Melanoma Drug Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Melanoma Drug Market, by Type
  7. Melanoma Drug Market, by Product
  8. Melanoma Drug Market, by Distribution Channel
  9. Americas Melanoma Drug Market
  10. Asia-Pacific Melanoma Drug Market
  11. Europe, Middle East & Africa Melanoma Drug Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 644]
  16. List of Companies Mentioned [Total: 24]
Frequently Asked Questions
  1. How big is the Melanoma Drug Market?
    Ans. The Global Melanoma Drug Market size was estimated at USD 5.40 billion in 2023 and expected to reach USD 5.81 billion in 2024.
  2. What is the Melanoma Drug Market growth?
    Ans. The Global Melanoma Drug Market to grow USD 9.45 billion by 2030, at a CAGR of 8.32%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.